Table 2.

Matching table on myositis therapy interactions in combination with novel antineoplastic therapies

This classification is based in the Anatomical Therapeutic Chemical (ATC) World Health Organization (WHO) 2022 system (https://www.whocc.no/atc_ddd_index/). “X” means a group interaction exists; “– “ means a group interaction was not found

ALK anaplastic lymphoma kinase, BRAF B-Raf serine-threonine kinase, BTK Bruton’s tyrosine kinase, CD clusters of differentiation, CDK cyclin-dependent kinase, EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, MEK mitogen-activated protein kinase, HER2 human epidermal growth factor receptor 2, JAK janus-associated kinase, mTOR mammalian target of rapamycin, PD-1/PDL-1 programmed cell death protein 1/death ligand 1, Pi3K phosphatidylinositol-3-kinase, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor